Protalix BioTherapeutics, Inc. (PLX)
USD 2.26
(-3.63%)
USD 2.26
(-3.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 10.46 Million USD | 180.37% |
| 2022 | -13.01 Million USD | 36.4% |
| 2021 | -20.46 Million USD | -1208.45% |
| 2020 | 1.84 Million USD | 117.22% |
| 2019 | -10.71 Million USD | 44.49% |
| 2018 | -19.3 Million USD | 46.89% |
| 2017 | -36.35 Million USD | -9.62% |
| 2016 | -33.16 Million USD | -40.11% |
| 2015 | -23.67 Million USD | 6.09% |
| 2014 | -25.2 Million USD | 7.05% |
| 2013 | -27.11 Million USD | -122.77% |
| 2012 | -12.17 Million USD | 66.68% |
| 2011 | -36.53 Million USD | -21.91% |
| 2010 | -29.96 Million USD | 6.27% |
| 2009 | -31.96 Million USD | -32.26% |
| 2008 | -24.17 Million USD | 1.61% |
| 2007 | -24.56 Million USD | -151.43% |
| 2006 | -9.77 Million USD | -10373.23% |
| 2005 | -93.29 Thousand USD | 43.66% |
| 2004 | -165.58 Thousand USD | -12.35% |
| 2003 | -147.38 Thousand USD | 11.1% |
| 2002 | -165.79 Thousand USD | 57.03% |
| 2001 | -385.78 Thousand USD | -1.03% |
| 2000 | -381.85 Thousand USD | 53.22% |
| 1999 | -816.21 Thousand USD | 30.48% |
| 1998 | -1.17 Million USD | -614.23% |
| 1997 | -164.38 Thousand USD | -273.1% |
| 1996 | -44.05 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.85 Million USD | 13.52% |
| 2024 Q2 | -2.42 Million USD | 50.02% |
| 2023 Q1 | -2.45 Million USD | 1.44% |
| 2023 FY | 10.46 Million USD | 180.37% |
| 2023 Q3 | -1.88 Million USD | -109.24% |
| 2023 Q2 | 20.42 Million USD | 930.46% |
| 2023 Q4 | -5.61 Million USD | -197.56% |
| 2022 Q1 | -1.87 Million USD | 67.23% |
| 2022 Q2 | -5.52 Million USD | -195.4% |
| 2022 Q3 | -3.12 Million USD | 43.43% |
| 2022 FY | -13.01 Million USD | 36.4% |
| 2022 Q4 | -2.49 Million USD | 20.16% |
| 2021 Q2 | -9.16 Million USD | -147.4% |
| 2021 Q1 | -3.7 Million USD | -230.5% |
| 2021 Q3 | -1.88 Million USD | 79.43% |
| 2021 FY | -20.46 Million USD | -1208.45% |
| 2021 Q4 | -5.7 Million USD | -202.71% |
| 2020 Q4 | 2.83 Million USD | 209.95% |
| 2020 Q1 | 4.69 Million USD | 113.32% |
| 2020 Q2 | -2.24 Million USD | -147.73% |
| 2020 Q3 | -2.58 Million USD | -15.27% |
| 2020 FY | 1.84 Million USD | 117.22% |
| 2019 Q3 | -1.54 Million USD | 73.56% |
| 2019 FY | -10.71 Million USD | 44.49% |
| 2019 Q1 | -5.53 Million USD | -147.94% |
| 2019 Q2 | -5.83 Million USD | -5.51% |
| 2019 Q4 | 2.2 Million USD | 242.49% |
| 2018 Q4 | 11.54 Million USD | 182.67% |
| 2018 Q3 | -13.96 Million USD | -45.81% |
| 2018 Q1 | -7.31 Million USD | 35.96% |
| 2018 FY | -19.3 Million USD | 46.89% |
| 2018 Q2 | -9.57 Million USD | -30.96% |
| 2017 FY | -36.35 Million USD | -9.62% |
| 2017 Q2 | -10.8 Million USD | -69.76% |
| 2017 Q4 | -11.41 Million USD | -47.04% |
| 2017 Q3 | -7.76 Million USD | 28.14% |
| 2017 Q1 | -6.36 Million USD | 27.01% |
| 2016 Q1 | -7.86 Million USD | 31.9% |
| 2016 Q3 | -6.64 Million USD | 33.06% |
| 2016 Q2 | -9.93 Million USD | -26.28% |
| 2016 FY | -33.16 Million USD | -40.11% |
| 2016 Q4 | -8.72 Million USD | -31.17% |
| 2015 Q2 | -4.47 Million USD | 7.66% |
| 2015 FY | -23.67 Million USD | 6.09% |
| 2015 Q4 | -11.54 Million USD | -311.4% |
| 2015 Q3 | -2.8 Million USD | 37.23% |
| 2015 Q1 | -4.84 Million USD | 31.61% |
| 2014 FY | -25.2 Million USD | 7.05% |
| 2014 Q4 | -7.08 Million USD | -14.06% |
| 2014 Q1 | -6.46 Million USD | 36.26% |
| 2014 Q3 | -6.2 Million USD | -13.97% |
| 2014 Q2 | -5.44 Million USD | 15.79% |
| 2013 Q1 | -4.42 Million USD | 56.44% |
| 2013 Q3 | -5.64 Million USD | 18.12% |
| 2013 FY | -27.11 Million USD | -122.77% |
| 2013 Q4 | -10.14 Million USD | -79.77% |
| 2013 Q2 | -6.89 Million USD | -55.66% |
| 2012 FY | -12.17 Million USD | 66.68% |
| 2012 Q4 | -10.16 Million USD | -82.86% |
| 2012 Q3 | -5.56 Million USD | -157.8% |
| 2012 Q1 | -6.06 Million USD | 31.53% |
| 2012 Q2 | 9.62 Million USD | 258.62% |
| 2011 Q3 | -8.76 Million USD | 36.78% |
| 2011 Q2 | -13.86 Million USD | -175.27% |
| 2011 Q1 | -5.03 Million USD | 43.06% |
| 2011 Q4 | -8.85 Million USD | -1.04% |
| 2011 FY | -36.53 Million USD | -21.91% |
| 2010 Q2 | -10.15 Million USD | -25.0% |
| 2010 Q3 | -2.84 Million USD | 71.94% |
| 2010 FY | -29.96 Million USD | 6.27% |
| 2010 Q4 | -8.84 Million USD | -210.67% |
| 2010 Q1 | -8.12 Million USD | 45.92% |
| 2009 Q4 | -15.01 Million USD | -148.35% |
| 2009 Q3 | -6.04 Million USD | -2.95% |
| 2009 Q2 | -5.87 Million USD | -16.64% |
| 2009 FY | -31.96 Million USD | -32.26% |
| 2009 Q1 | -5.03 Million USD | 19.98% |
| 2008 Q2 | -4.89 Million USD | 21.79% |
| 2008 FY | -24.17 Million USD | 1.61% |
| 2008 Q4 | -6.29 Million USD | 6.34% |
| 2008 Q1 | -6.26 Million USD | -4.04% |
| 2008 Q3 | -6.71 Million USD | -37.16% |
| 2007 Q2 | -13.11 Million USD | -246.89% |
| 2007 FY | -24.56 Million USD | -151.43% |
| 2007 Q4 | -6.02 Million USD | 6.39% |
| 2007 Q3 | -6.43 Million USD | 50.97% |
| 2007 Q1 | -3.78 Million USD | 60.64% |
| 2006 Q2 | -26.11 Thousand USD | -23.69% |
| 2006 Q1 | -21.11 Thousand USD | 19.12% |
| 2006 FY | -9.77 Million USD | -10373.23% |
| 2006 Q4 | -9.6 Million USD | -8067.11% |
| 2006 Q3 | -117.62 Thousand USD | -350.44% |
| 2005 FY | -93.29 Thousand USD | 43.66% |
| 2005 Q4 | -26.1 Thousand USD | 27.26% |
| 2005 Q3 | -35.88 Thousand USD | -75.52% |
| 2005 Q2 | -20.44 Thousand USD | -88.21% |
| 2005 Q1 | -10.86 Thousand USD | 66.17% |
| 2004 Q3 | -43.88 Thousand USD | 26.75% |
| 2004 Q1 | -29.68 Thousand USD | 39.24% |
| 2004 Q2 | -59.9 Thousand USD | -101.82% |
| 2004 Q4 | -32.1 Thousand USD | 26.83% |
| 2004 FY | -165.58 Thousand USD | -12.35% |
| 2003 Q1 | -34.55 Thousand USD | 34.23% |
| 2003 FY | -147.38 Thousand USD | 11.1% |
| 2003 Q2 | -30.96 Thousand USD | 10.39% |
| 2003 Q3 | -33.01 Thousand USD | -6.64% |
| 2003 Q4 | -48.85 Thousand USD | -47.96% |
| 2002 Q1 | -40.62 Thousand USD | 74.0% |
| 2002 Q2 | -36.87 Thousand USD | 9.23% |
| 2002 Q4 | -52.53 Thousand USD | -46.9% |
| 2002 Q3 | -35.76 Thousand USD | 3.02% |
| 2002 FY | -165.79 Thousand USD | 57.03% |
| 2001 Q3 | -58.67 Thousand USD | 9.8% |
| 2001 FY | -385.78 Thousand USD | -1.03% |
| 2001 Q2 | -65.04 Thousand USD | 38.53% |
| 2001 Q1 | -105.82 Thousand USD | 51.96% |
| 2001 Q4 | -156.24 Thousand USD | -166.3% |
| 2000 Q3 | -15.57 Thousand USD | 79.99% |
| 2000 FY | -381.85 Thousand USD | 53.22% |
| 2000 Q1 | -68.17 Thousand USD | 51.67% |
| 2000 Q4 | -220.29 Thousand USD | -1314.67% |
| 2000 Q2 | -77.8 Thousand USD | -14.12% |
| 1999 Q2 | -178.94 Thousand USD | -147.13% |
| 1999 Q1 | -72.4 Thousand USD | 92.13% |
| 1999 FY | -816.21 Thousand USD | 30.48% |
| 1999 Q4 | -141.07 Thousand USD | 66.71% |
| 1999 Q3 | -423.79 Thousand USD | -136.83% |
| 1998 Q1 | -190 Thousand USD | 0.0% |
| 1998 Q2 | -20 Thousand USD | 89.47% |
| 1998 Q3 | -40 Thousand USD | -100.0% |
| 1998 Q4 | -920 Thousand USD | -2200.0% |
| 1998 FY | -1.17 Million USD | -614.23% |
| 1997 Q2 | -140 Thousand USD | -40.0% |
| 1997 Q3 | -200 Thousand USD | -42.86% |
| 1997 Q4 | -190 Thousand USD | 5.0% |
| 1997 FY | -164.38 Thousand USD | -273.1% |
| 1997 Q1 | -100 Thousand USD | -400.0% |
| 1996 FY | -44.05 Thousand USD | 0.0% |
| 1996 Q3 | -10 Thousand USD | 0.0% |
| 1996 Q4 | -20 Thousand USD | -100.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 132.774% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 209.897% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 125.581% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 120.146% |
| Azitra, Inc. | -7.61 Million USD | 237.335% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | 227.639% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | 252.427% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 136.079% |
| CEL-SCI Corporation | -31.47 Million USD | 133.232% |
| iBio, Inc. | -16.63 Million USD | 162.883% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 142.292% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 151.827% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 144.012% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 174.444% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | 309.075% |
| NanoViricides, Inc. | -8.51 Million USD | 222.826% |
| Oragenics, Inc. | -20.9 Million USD | 150.036% |
| BiomX Inc. | -27.68 Million USD | 137.782% |
| BiomX Inc. | -27.68 Million USD | 137.782% |
| Palatin Technologies, Inc. | -22.49 Million USD | 146.497% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 124.886% |
| Theriva Biologics, Inc. | -21.43 Million USD | 148.808% |